X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
zd6474 (216) 216
humans (162) 162
oncology (126) 126
index medicus (124) 124
vandetanib (85) 85
animals (74) 74
angiogenesis (73) 73
female (70) 70
tyrosine kinase inhibitor (69) 69
cancer (67) 67
quinazolines - therapeutic use (63) 63
piperidines - therapeutic use (60) 60
endothelial growth-factor (58) 58
quinazolines - pharmacology (57) 57
piperidines - pharmacology (54) 54
inhibitor (53) 53
quinazolines - administration & dosage (53) 53
male (51) 51
piperidines - administration & dosage (51) 51
mice (50) 50
middle aged (44) 44
pharmacology & pharmacy (43) 43
antineoplastic agents - therapeutic use (42) 42
cell line, tumor (41) 41
aged (40) 40
lung neoplasms - drug therapy (39) 39
piperidines - adverse effects (39) 39
quinazolines - adverse effects (39) 39
vascular endothelial growth factor (37) 37
antitumor-activity (36) 36
carcinoma, non-small-cell lung - drug therapy (36) 36
gefitinib (35) 35
vegf (35) 35
malignant-tumors (33) 33
receptor, epidermal growth factor - antagonists & inhibitors (33) 33
antineoplastic agents - pharmacology (32) 32
egfr (32) 32
adult (31) 31
cell lung-cancer (31) 31
therapy (30) 30
carcinoma (29) 29
tumor-growth (29) 29
bevacizumab (28) 28
growth-factor receptor (28) 28
treatment outcome (28) 28
double-blind (27) 27
combination (26) 26
receptor tyrosine kinase (26) 26
thyroid neoplasms - drug therapy (26) 26
antineoplastic agents - adverse effects (25) 25
antineoplastic combined chemotherapy protocols - therapeutic use (25) 25
mice, nude (25) 25
care and treatment (24) 24
protein kinase inhibitors - therapeutic use (24) 24
thyroid cancer (24) 24
drug therapy (23) 23
medicine & public health (23) 23
xenograft model antitumor assays (23) 23
piperidines - pharmacokinetics (22) 22
protein kinase inhibitors - pharmacology (22) 22
quinazolines - pharmacokinetics (22) 22
receptors, vascular endothelial growth factor - antagonists & inhibitors (22) 22
angiogenesis inhibitors - therapeutic use (21) 21
apoptosis - drug effects (21) 21
article (21) 21
expression (21) 21
phase-ii (21) 21
chemotherapy (20) 20
clinical trials (20) 20
erlotinib (20) 20
factor receptor (20) 20
analysis (19) 19
cell proliferation - drug effects (19) 19
disease-free survival (19) 19
receptor, epidermal growth factor - metabolism (19) 19
tyrosine (19) 19
tyrosine kinase (19) 19
epidermal growth factor (18) 18
lung-cancer (18) 18
mutations (18) 18
antineoplastic agents - administration & dosage (17) 17
lung cancer (17) 17
protein kinase inhibitors - administration & dosage (17) 17
research (17) 17
thyroid neoplasms - pathology (17) 17
dose-response relationship, drug (16) 16
growth (16) 16
trial (16) 16
tumors (16) 16
antineoplastic agents (15) 15
neovascularization, pathologic - drug therapy (15) 15
protein-tyrosine kinases - antagonists & inhibitors (15) 15
ret (15) 15
aged, 80 and over (14) 14
cells (14) 14
clinical trials as topic (14) 14
epidermal growth factor receptor (14) 14
neoplasm metastasis (14) 14
pharmacokinetics (14) 14
protein kinase inhibitors - adverse effects (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 897 - 905
Summary Background No effective standard treatment exists for patients with radioiodine-refractory, advanced differentiated thyroid carcinoma. We aimed to... 
Hematology, Oncology and Palliative Medicine | CRITERIA | MALIGNANT-TUMORS | SOLID TUMORS | ONCOLOGY | PAPILLARY | SORAFENIB | INHIBITOR | CARCINOMA | ZD6474 | Carcinoma | Humans | Middle Aged | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Diarrhea - chemically induced | Young Adult | Lung Neoplasms - secondary | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | ErbB Receptors - antagonists & inhibitors | Thyroid Neoplasms - mortality | Double-Blind Method | Kaplan-Meier Estimate | Electrocardiography - drug effects | Heart Conduction System - drug effects | Lymphatic Metastasis | Thyroid Cancer, Papillary | Disease-Free Survival | Adenocarcinoma, Follicular | Thyroid Neoplasms - drug therapy | Carcinoma, Papillary | Piperidines - therapeutic use | Quinazolines - therapeutic use | Piperidines - adverse effects | Adolescent | Quinazolines - adverse effects | Skin Neoplasms - secondary | Survival Analysis | Thyroid Neoplasms - secondary | Aged | Thyroid Neoplasms - pathology | Tyrosine | Care and treatment | Thyroid cancer | Clinical trials | Product development | Metastasis | Vascular endothelial growth factor | Cancer | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
International Journal of Cancer, ISSN 0020-7136, 05/2016, Volume 138, Issue 10, pp. 2510 - 2521
The receptor tyrosine kinase RET is implicated in the progression of luminal breast cancers (BC) but its role in estrogen receptor (ER) negative tumors is... 
RET | breast cancer | vandetanib | PDX models | CELLS | QUANTIFICATION | KINASE INHIBITOR SELECTIVITY | ZD6474 | THERAPY | GENE | ONCOLOGY | TUMOR-GROWTH | EXPRESSION | XENOGRAFTS | Proto-Oncogene Proteins c-ret - metabolism | Receptors, Estrogen - metabolism | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Receptors, Estrogen - deficiency | Molecular Targeted Therapy | Biomarkers, Tumor | Breast Neoplasms - metabolism | Neoplasm Metastasis | Neoplasm Grading | Receptors, Vascular Endothelial Growth Factor - metabolism | Piperidines - pharmacology | Aged, 80 and over | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Receptors, Vascular Endothelial Growth Factor - genetics | Disease Models, Animal | Gene Expression | RNA, Messenger - genetics | Breast Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Breast Neoplasms - genetics | MAP Kinase Signaling System - drug effects | Tumor Burden - drug effects | Breast Neoplasms - pathology | Neovascularization, Pathologic - drug therapy | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Mice | Protein Kinase Inhibitors - pharmacology | Quinazolines - pharmacology | Proto-Oncogene Proteins c-ret - genetics | Care and treatment | Endothelial growth factors | Analysis | Estrogen | Phenols | Development and progression | Breast cancer | Chemotherapy | Kinases | Patients | Tumors | Phosphorylation | Animal models | Estrogens | Estrogen receptors | Vascularization | Receptors | Ret protein | Transfection | Epidermal growth factor | Xenografts | Protein-tyrosine kinase receptors | Inhibition | Vascular endothelial growth factor | Protein-tyrosine kinase | Tyrosine | Epidermal growth factor receptors | MAP kinase | Regression analysis | ErbB-2 protein | Polymerase chain reaction | Inhibitors | Breast | Cancer
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 767 - 772
Purpose There is no effective therapy for patients with distant metastasis of medullary thyroid carcinoma (MTC). Activating mutations in the RET proto-oncogene... 
MALIGNANT-TUMORS | ANGIOGENESIS | ONCOLOGY | GROWTH | MUTATIONS | INHIBITOR | CARCINOMA | EXPRESSION | RET PROTOONCOGENE | ZD6474 | KINASES | Carcinoembryonic Antigen - blood | United States | Humans | Middle Aged | Carcinoma, Medullary - metabolism | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Young Adult | Carcinoma, Medullary - drug therapy | Carcinoma, Medullary - secondary | Time Factors | Antineoplastic Agents - adverse effects | Germ-Line Mutation | Adult | Female | Quinazolines - administration & dosage | France | Proto-Oncogene Proteins c-ret - antagonists & inhibitors | Calcitonin - blood | Genetic Predisposition to Disease | Piperidines - administration & dosage | Thyroid Neoplasms - mortality | Carcinoma, Medullary - mortality | Drug Administration Schedule | Administration, Oral | Carcinoma, Medullary - genetics | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Biomarkers, Tumor - blood | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Thyroid Neoplasms - genetics | Thyroid Neoplasms - drug therapy | Pedigree | Piperidines - adverse effects | Quinazolines - adverse effects | Aged | Proto-Oncogene Proteins c-ret - genetics | Thyroid Neoplasms - metabolism | Thyroid Neoplasms - pathology | Index Medicus | Hnc7 | Original Reports | Endo7 | To8
Journal Article
Endocrine-related cancer, ISSN 1351-0088, 02/2019, Volume 26, Issue 2, pp. 241 - 250
Vandetanib is an oral tyrosine kinase inhibitor approved for treatment of advanced symptomatic or progressive medullary thyroid cancer (MTC). The current study... 
medullary thyroid cancer | vandetanib | safety | efficacy | SURVIVAL | MANAGEMENT | ONCOLOGY | GUIDELINES | ENDOCRINOLOGY & METABOLISM | CARCINOMA | ZD6474
Journal Article
ACS CHEMICAL BIOLOGY, ISSN 1554-8929, 09/2019, Volume 14, Issue 9, pp. 1930 - 1939
Unstable atropisomerism is innate in many common scaffolds in drug discovery, commonly existing as freely rotating aryl-aryl bonds. Such compounds can access... 
VANDETANIB ZD6474 | LUNG-CANCER | C797S RESISTANCE | DESIGN | DISEASE PHENOTYPE | BIOCHEMISTRY & MOLECULAR BIOLOGY | IN-VIVO | MUTATION | MECHANISMS | PROTOONCOGENE | DISCOVERY
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2013, Volume 19, Issue 15, pp. 4239 - 4248
Journal Article
Journal Article
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, ISSN 1386-1425, 04/2019, Volume 213, pp. 272 - 280
A highly sensitive and accurate novel response surface methodology (RSM)-assisted micellar enhanced synchronous spectrofluorimetric method was developed and... 
Synchronous spectrofluorimetry | Vandetanib | Human plasma | Response surface methodology | Human urine | TYROSINE KINASE | DASATINIB | CANCER | ZD6474 | LIQUID-CHROMATOGRAPHY | SPECTROSCOPY | OPTIMIZATION | INHIBITOR | Surface active agents | Castor oil | Analysis | Pharmacy | Fluorescence | Drugstores | Liquid chromatography | Methods
Journal Article
Annals of Oncology, ISSN 0923-7534, 2011, Volume 22, Issue 6, pp. 1374 - 1381
Journal Article
Journal Article